Sandoz Receives Corporate Circle Award from the Crohn’s & Colitis Foundation, Marking the First Time an Emerging Partner Has Received this Honor
DENVER – On Friday, Jan. 20, Sandoz was presented with the Corporate Circle Award at the Crohn’s & Colitis Foundation’s annual President’s Corporate Circle reception held during the Crohn’s & Colitis Congress®.
The Crohn’s & Colitis Foundation is a non-profit, volunteer-fueled organization dedicated to finding cures for Crohn's disease and ulcerative colitis, and to improving the quality of life of children and adults affected by these diseases, which are collectively referred to as inflammatory bowel disease (IBD).
President’s Corporate Circle Awards have historically been given to large industry partners who have made a significant impact in the IBD space. This is the first time that an award has been given to an emerging partner, and the Foundation cited Sandoz’ partnership in advancing the Foundation’s mission over the past year as the impetus for the decision to introduce this new award recognizing a more recent player in the disease area. Sandoz will launch an IBD therapy pending FDA approval of its adalimumab biosimilar later this year.
Specifically, in 2022, Sandoz US hosted its first-ever Patient Experience Townhall in collaboration with the Foundation, so that all associates could hear and embed patient insights into the work we do every day to pioneer access to much needed medicines. As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. To that end, Sandoz also co-sponsored the Foundation’s Biosimilar Professional Education Initiative, which can be found here.